Aaron P Thrift1,2, Jennifer R Kramer2,3,4, Christine M Hartman3, Kathryn Royse3, Peter Richardson3, Yongquan Dong3, Suchismita Raychaudhury3, Roxanne Desiderio3, Dina Sanchez3, Sharmila Anandasabapathy5, Donna L White2,3,4,5,6, Elizabeth Y Chiao2,3,4,7. 1. Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX. 2. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX. 3. Clinical Epidemiology and Comparative Effectiveness Program, VA Health Services Research Center of Innovations (IQuESt), Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX. 4. Texas Medical Center Digestive Diseases Center, Houston, TX. 5. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX. 6. Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX. 7. Section of Infectious Disease, Department of Medicine, Baylor College of Medicine, Houston, TX.
Abstract
BACKGROUND: To evaluate the risks of esophageal and stomach carcinomas in people living with HIV (PLWH) compared with the general population and risk factors for these cancers in PLWH. SETTING: Retrospective cohort study in the Veterans Health Administration. METHODS: We compared incidence rates for esophageal and stomach cancers in 44,075 HIV-infected male veterans with those in a matched HIV-uninfected cohort (N = 157,705; 4:1 matched on age and HIV-index date). We used Cox regression models to estimate Hazard ratios (HRs) and 95% confidence intervals (CIs) for associations with HIV infection and for cancer risk factors in PLWH. RESULTS: In unadjusted models, HIV infection was associated with increased risks of esophageal squamous cell carcinoma (ESCC; HR, 2.21; 95% CI: 1.47 to 3.13) and gastric cardia cancer (HR, 1.69; 95% CI: 1.00 to 2.85) but associated with lower risk of esophageal adenocarcinoma (EAC; HR, 0.48; 95% CI: 0.31 to 0.74). After adjusting for age, race/ethnicity, smoking and alcohol use, HIV infection remained statistically significantly associated with elevated risk for ESCC [adjusted hazard ratio (aHR), 1.58; 95% CI: 1.02 to 2.47], especially among HIV-infected patients with CD4 count ≤200 (aHR, 2.20; 95% CI: 1.35 to 3.60). HIV infection was not associated with risks of EAC (aHR, 0.82; 95% CI: 0.53 to 1.26), gastric cardia (aHR, 0.80; 95% CI: 0.33 to 1.94), or noncardia (aHR, 1.06; 95% CI: 0.61 to 1.84) cancers. Risk factors for these cancers in HIV-infected patients were otherwise similar to those in general population (eg, Helicobacter pylori for gastric noncardia cancer). CONCLUSION: HIV-infected individuals with low CD4 count are at highest risk for ESCC, but HIV infection was not independently associated with EAC or gastric cancer after adjusting for confounders.
BACKGROUND: To evaluate the risks of esophageal and stomach carcinomas in people living with HIV (PLWH) compared with the general population and risk factors for these cancers in PLWH. SETTING: Retrospective cohort study in the Veterans Health Administration. METHODS: We compared incidence rates for esophageal and stomach cancers in 44,075 HIV-infected male veterans with those in a matched HIV-uninfected cohort (N = 157,705; 4:1 matched on age and HIV-index date). We used Cox regression models to estimate Hazard ratios (HRs) and 95% confidence intervals (CIs) for associations with HIV infection and for cancer risk factors in PLWH. RESULTS: In unadjusted models, HIV infection was associated with increased risks of esophageal squamous cell carcinoma (ESCC; HR, 2.21; 95% CI: 1.47 to 3.13) and gastric cardia cancer (HR, 1.69; 95% CI: 1.00 to 2.85) but associated with lower risk of esophageal adenocarcinoma (EAC; HR, 0.48; 95% CI: 0.31 to 0.74). After adjusting for age, race/ethnicity, smoking and alcohol use, HIV infection remained statistically significantly associated with elevated risk for ESCC [adjusted hazard ratio (aHR), 1.58; 95% CI: 1.02 to 2.47], especially among HIV-infectedpatients with CD4 count ≤200 (aHR, 2.20; 95% CI: 1.35 to 3.60). HIV infection was not associated with risks of EAC (aHR, 0.82; 95% CI: 0.53 to 1.26), gastric cardia (aHR, 0.80; 95% CI: 0.33 to 1.94), or noncardia (aHR, 1.06; 95% CI: 0.61 to 1.84) cancers. Risk factors for these cancers in HIV-infectedpatients were otherwise similar to those in general population (eg, Helicobacter pylori for gastric noncardia cancer). CONCLUSION:HIV-infected individuals with low CD4 count are at highest risk for ESCC, but HIV infection was not independently associated with EAC or gastric cancer after adjusting for confounders.
Authors: Leah L Zullig; George L Jackson; Raye Anne Dorn; Dawn T Provenzale; Rebecca McNeil; Catherine M Thomas; Michael J Kelley Journal: Mil Med Date: 2012-06 Impact factor: 1.437
Authors: Frank H Galvan; Eric G Bing; John A Fleishman; Andrew S London; Raul Caetano; M Audrey Burnam; Doug Longshore; Sally C Morton; Maria Orlando; Martin Shapiro Journal: J Stud Alcohol Date: 2002-03
Authors: Rennatus Mdodo; Emma L Frazier; Shanta R Dube; Christine L Mattson; Madeline Y Sutton; John T Brooks; Jacek Skarbinski Journal: Ann Intern Med Date: 2015-03-03 Impact factor: 25.391
Authors: George L Jackson; L Douglas Melton; David H Abbott; Leah L Zullig; Diana L Ordin; Steven C Grambow; Natia S Hamilton; S Yousuf Zafar; Ziad F Gellad; Michael J Kelley; Dawn Provenzale Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Marc A Kowalkowski; Rena S Day; Xianglin L Du; Wenyaw Chan; Elizabeth Y Chiao Journal: J Acquir Immune Defic Syndr Date: 2014-10-01 Impact factor: 3.731
Authors: Natalie E Chichetto; Brittanny M Polanka; Kaku A So-Armah; Minhee Sung; Jesse C Stewart; John R Koethe; E Jennifer Edelman; Hilary A Tindle; Matthew S Freiberg Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.495
Authors: Angela L Mazul; Christine Hartman; Jennifer Kramer; Donna L White; Kathryn Royse; Suchismita Raychaudhury; Vlad Sandulache; Sarah T Ahmed; Peter Richardson; Andrew G Sikora; Elizabeth Chiao Journal: Cancer Med Date: 2020-10-23 Impact factor: 4.452